Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

被引:99
作者
Pao, D
Andrady, U
Clarke, J
Dean, G
Drake, S
Fisher, M
Green, T
Kumar, S
Murphy, M
Tang, A
Taylor, S
White, D
Underhill, G
Pillay, D
Cane, P [1 ]
机构
[1] Univ Birmingham, Sch Med, Div Immun & Infect, Antiviral Susceptibil Reference Unit,Hlth Protec, Birmingham B15 2TT, W Midlands, England
[2] Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England
[3] Ys Byty Gwynedd, Bangor, Gwynedd, Wales
[4] Leeds Gen Infirm, Leeds, W Yorkshire, England
[5] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England
[6] Pinderfields Gen Hosp, Wakefield, England
[7] Queen Elizabeth Hosp, Kings Lynn, England
[8] St Bartholomews Hosp, London, England
[9] Royal Berkshire Hosp, Reading RG1 5AN, Berks, England
[10] Portsmouth Hosp, Natl Hlth Serv Trust, Portsmouth, Hants, England
[11] UCL, London, England
关键词
HIV-1; primary drug resistance; persistence of mutations;
D O I
10.1097/00126334-200412150-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.
引用
收藏
页码:1570 / 1573
页数:4
相关论文
共 22 条
[1]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[2]   Resistance to antiretroviral drugs in patients with primary HIV-1 infection [J].
Brenner, B ;
Wainberg, MA ;
Salomon, H ;
Rouleau, D ;
Dascal, A ;
Spira, B ;
Sekaly, RP ;
Conway, B ;
Routy, JP .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (04) :429-434
[3]   Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].
Brenner, BG ;
Routy, JP ;
Petrella, M ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Spira, B ;
Essabag, V ;
Conway, B ;
Lalonde, R ;
Sekaly, RP ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761
[4]   HETEROSEXUAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS ASSOCIATED WITH ZIDOVUDINE RESISTANCE [J].
CONLON, CP ;
KLENERMAN, P ;
EDWARDS, A ;
LARDER, BA ;
PHILLIPS, RE .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :411-415
[5]   Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type I drug resistance [J].
De Luca, A ;
Cingolani, A ;
Di Giambenedetto, S ;
Trotta, MP ;
Baldini, F ;
Rizzo, MG ;
Bertoli, A ;
Liuzzi, G ;
Narciso, P ;
Murri, R ;
Antmassari, A ;
Perno, CF ;
Antinori, A .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1934-1943
[6]   Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus [J].
de Ronde, A ;
van Dooren, M ;
van der Hoek, L ;
Bouwhuis, D ;
de Rooij, E ;
van Gemen, B ;
de Boer, R ;
Goudsmit, J .
JOURNAL OF VIROLOGY, 2001, 75 (02) :595-602
[7]   Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure [J].
Delaugerre, C ;
Valantin, MA ;
Mouroux, M ;
Bonmarchand, M ;
Carcelain, G ;
Duvivier, C ;
Tubiana, R ;
Simon, A ;
Bricaire, F ;
Agut, H ;
Autran, B ;
Katlama, C ;
Calvez, V .
AIDS, 2001, 15 (16) :2189-2191
[8]   Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study [J].
Duwe, S ;
Brunn, M ;
Altmann, D ;
Hamouda, O ;
Schmidt, B ;
Walter, H ;
Pauli, G ;
Kücherer, C .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) :266-273
[9]   Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons [J].
García-Lerma, JG ;
Nidtha, S ;
Blumoff, K ;
Weinstock, H ;
Heneine, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13907-13912
[10]   Time trends in primary HIV-1 drug resistance among recently infected persons [J].
Grant, RM ;
Hecht, FM ;
Warmerdam, M ;
Liu, L ;
Liegler, T ;
Petropoulos, CJ ;
Hellmann, NS ;
Chesney, M ;
Busch, MP ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :181-188